Argenica Therapeutics Ltd (AGN) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 68.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: 6.81%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 128,092,850
• 10 Day Avg. Volume: 70,456
• 30 Day Avg. Volume: 68,559
• PEG Ratio: -1.09
• Price to Book (P/B): 7.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -18.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.19
• Price Target Upside: 63.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Argenica Therapeutics Ltd has a score of 48.2, driven by strong revenue growth but ongoing operational challenges. The robust balance sheet without debt offers stability, yet negative cash flows highlight financial risks. Technical analysis suggests bearish momentum, and valuation metrics indicate potential overvaluation given current earnings performance.

Argenica Therapeutics Ltd Business Overview & Revenue Model

Company Description

Argenica Therapeutics Ltd (AGN) is a biotechnology company focused on developing novel treatments to reduce brain tissue damage after stroke and other types of brain injuries. The company's primary product is a neuroprotective therapeutic aimed at mitigating the impact of ischemic stroke, which remains a leading cause of death and disability worldwide. Argenica operates within the pharmaceutical and healthcare sectors, leveraging cutting-edge research and development to address significant unmet medical needs.

How the Company Makes Money

Argenica Therapeutics makes money primarily through the development and commercialization of its neuroprotective therapeutic products. The company's revenue model includes securing funding through partnerships with larger pharmaceutical companies, grants, and potential licensing agreements for its core technologies. As a biotech firm, Argenica is focused on advancing its product pipeline through clinical trials to achieve regulatory approval, which can lead to revenue generation through product sales, licensing, or strategic partnerships with established players in the pharmaceutical industry. Additionally, the company may benefit from government or private sector grants aimed at fostering innovation in medical treatments.

Argenica Therapeutics Ltd Financial Statement Overview

Summary

Argenica Therapeutics Ltd demonstrates strong revenue growth typical for high-growth biotech firms, but faces operational losses as reflected in negative EBIT and net income margins. The balance sheet is strong with no debt, providing financial stability, yet cash flows are negative, indicating reliance on external financing.

Income Statement

Argenica Therapeutics Ltd shows impressive revenue growth with a positive trend over recent periods. However, the company is operating at a loss, as indicated by negative EBIT and net income margins. The gross profit margin remains high at 100%, but the negative net profit margin and EBIT margin suggest ongoing operational challenges.

Balance Sheet

The company boasts a strong equity position with no debt, as indicated by a debt-to-equity ratio of zero. Stockholders' equity has been increasing, resulting in a healthy equity ratio. The return on equity is negative due to net losses, which is typical for companies in the early stages of biotech development.

Cash Flow

Argenica Therapeutics' cash flow statement reveals significant reliance on financing activities to support operations, as seen in high financing cash flow. The operating cash flow and free cash flow are negative, which is concerning but not uncommon for growth-focused biotech firms. The free cash flow to net income ratio is unfavorable, reflecting operational cash constraints.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
3.08M	2.60M	1.75M	259.10K	296.07K	0.00
	Gross Profit
3.08M	2.60M	1.75M	259.10K	296.07K	0.00
	EBIT
-5.67M	-5.67M	-6.62M	-4.09M	-1.03M	-383.65K
	EBITDA
-1.96M	-1.90M	0.00	0.00	0.00	0.00
	Net Income Common Stockholders
-5.26M	-5.48M	-4.82M	-4.09M	-1.03M	-383.40K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
15.08M	15.91M	9.34M	8.91M	7.14M	341.98K
	Total Assets
15.41M	16.38M	9.54M	9.04M	7.27M	377.66K
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-15.08M	-15.91M	-9.29M	-8.91M	-7.14M	-341.98K
	Total Liabilities
2.22M	2.43M	1.87M	735.91K	425.72K	359.26K
	Stockholders Equity
13.19M	13.95M	7.67M	8.31M	6.85M	18.40K
Cash Flow		Free Cash Flow
-5.10M	-5.06M	-3.30M	-3.36M	-1.05M	-58.82K
	Operating Cash Flow
-5.10M	-5.06M	-3.30M	-3.36M	-1.05M	-58.82K
	Investing Cash Flow
0.00	50.00K	-50.00K	0.00	0.00	0.00
	Financing Cash Flow
11.75M	11.63M	3.73M	5.13M	7.85M	400.80K

Argenica Therapeutics Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AGN, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.72, below the 50-day MA of 0.74, and below the 200-day MA of 0.74, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.98 is Neutral, neither overbought nor oversold. The STOCH value of 5.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AGN.

Argenica Therapeutics Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAC	54 Neutral	AU$251.04M	―	-37.20%	―	―	32.02%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
AGN	48 Neutral		―	-53.14%	―	―	6.81%
CYP	43 Neutral	$45.19M	―	-75.39%	―	―	44.29%
BIT	36 Underperform	$3.98M	―	-119.28%	―	―	64.10%

Argenica Therapeutics Ltd Corporate Events

Argenica Therapeutics Advances Phase 2 Trial for Stroke Treatment

Argenica Therapeutics has made significant progress in its Phase 2 clinical trial of ARG-007 for acute ischaemic stroke, with the final patient dosed and topline data expected in Q3 2025. The trial, which involves 92 patients, aims to assess the safety and efficacy of ARG-007, with results potentially impacting the company’s market positioning in stroke treatment. Additionally, preclinical studies suggest ARG-007 could prevent axonal injury and neuroinflammation in traumatic brain injury, further supporting its potential utility in neurological treatments.

Argenica Completes Dosing in Phase 2 Stroke Trial for ARG-007

Argenica Therapeutics has completed dosing the last patient in its Phase 2 clinical trial for ARG-007, a treatment aimed at reducing brain injury in acute ischaemic stroke patients. The trial, which involved 92 patients, will remain blinded until the final assessments are completed, with topline data expected in Q3 2025. This milestone underscores the company’s rapid progress in clinical development and highlights Australia’s strong capabilities in stroke research, potentially enhancing Argenica’s position in the biotechnology industry.

Argenica Therapeutics Announces Cessation of Securities

Argenica Therapeutics Ltd announced the cessation of 300,000 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.

Argenica Therapeutics Unveils Strategic Plans at Euroz Hartley’s Conference

Argenica Therapeutics Ltd presented at Euroz Hartley’s Rottnest Conference, emphasizing their strategic plans and future prospects. The presentation highlighted the company’s commitment to advancing its therapeutic pipeline, which could potentially strengthen its position in the biotech sector and offer promising developments for stakeholders.

Argenica Therapeutics Announces Director Departure

Argenica Therapeutics Ltd announced the cessation of Robert Black as a director, effective March 3, 2025. This change in the board may influence the company’s strategic direction and stakeholder interests, as Black held significant shares through Black Magic Enterprises Pty Ltd, indicating his substantial involvement in the company.

Argenica Therapeutics Announces Director Resignation

Argenica Therapeutics Limited announced the resignation of Mr. Rob Black as a Non-Executive Director, effective immediately, as he transitions to a full-time executive role in the financial services sector. This change may impact the company’s governance structure, but the board expressed gratitude for Mr. Black’s contributions and wished him success in his new position.

Argenica Therapeutics Reports Reduced Losses Amid Increased R&D Costs

Argenica Therapeutics Limited reported a 16% reduction in losses to $1,187,221 for the half-year ended 31 December 2024, despite increased research and development costs related to their ongoing clinical trials. The company’s other income rose by 29% due to a substantial R&D tax incentive rebate, highlighting its dependence on external funding and government support for continued operations and development.